Vaxcyte, Inc.

Vaxcyte, Inc. is a clinical-stage vaccine innovation company dedicated to engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. Headquartered in San Carlos, California, the company focuses on developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

The company's pipeline includes lead candidates VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV), and VAX-24, a 24-valent PCV, both being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31 is advancing to a Phase 3 adult clinical program and is also being evaluated in a Phase 2 infant clinical program, while VAX-24 is in a Phase 2 infant clinical program. Vaxcyte also has early-stage programs targeting Group A Strep (VAX-A1) and Shigella (VAX-GI), as well as a third-generation PCV candidate, VAX-XL. The company leverages its proprietary cell-free protein synthesis platform, XpressCF™, and advanced chemistry to produce complex proteins and antigens for its vaccine candidates.

Led by CEO Grant Pickering, Vaxcyte has recently completed enrollment in its OPUS-1 and OPUS-2 Phase 3 clinical trials for VAX-31, evaluating its efficacy against IPD and pneumonia in adults. Positive Phase 1/2 adult data for VAX-31 has been published in The Lancet Infectious Diseases, highlighting its potential. The company also reported VAX-24 infant study results in March 2025, with VAX-31 infant Phase 2 data anticipated in mid-2026. In May 2025, Vaxcyte strengthened its Board of Directors with the appointment of Dr. Olivier Brandicourt, former CEO of Sanofi. Vaxcyte maintains a strong financial position, with approximately $2.82 billion in cash and investments as of June 30, 2025.